Abstract
We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 178-181 |
| Number of pages | 4 |
| Journal | International Journal of Pharmaceutics |
| Volume | 557 |
| DOIs | |
| State | Published - Feb 25 2019 |
Fingerprint
Keywords
- Dendrimer
- EGFR
- Oral cancer
- Signal transduction
- Targeted therapy
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference. / Yuan, Quan; Yeudall, William Andrew; Lee, Eunmee; Yang, Hu.
In: International Journal of Pharmaceutics, Vol. 557, 25.02.2019, p. 178-181.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference
AU - Yuan, Quan
AU - Yeudall, William Andrew
AU - Lee, Eunmee
AU - Yang, Hu
PY - 2019/2/25
Y1 - 2019/2/25
N2 - We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.
AB - We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.
KW - Dendrimer
KW - EGFR
KW - Oral cancer
KW - Signal transduction
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85059532457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059532457&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2018.12.060
DO - 10.1016/j.ijpharm.2018.12.060
M3 - Article
C2 - 30597261
AN - SCOPUS:85059532457
VL - 557
SP - 178
EP - 181
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
ER -